Oncology Nursing News®

Register now to learn about a new option for relapsed or refractory follicular lymphoma

Brain Cancer

FDA OKs Berubicin for GBM Treatment

FDA OKs Berubicin for GBM Treatment

BY KRISTI ROSA

AV-GBM-1 Vaccine Improves Glioblastoma Outcomes

AV-GBM-1 Vaccine Improves Glioblastoma Outcomes

BY KRISTI ROSA

FDA Grants Fast Track Status to Paxalisib for GBM Treatment

FDA Grants Fast Track Status to Paxalisib for GBM Treatment

BY KRISTI ROSA

FDA Grants Fast Track Status to Enzastaurin to Treat Newly Diagnosed GBM

FDA Grants Fast Track Status to Enzastaurin to Treat Newly Diagnosed GBM

BY KRISTI ROSA

FDA Accepts BLA for Bevacizumab Biosimilar

FDA Accepts BLA for Bevacizumab Biosimilar

BY GINA COLUMBUS

Checkpoint Blockade Plus Vaccines Show Synergy in Early GBM Trials

Checkpoint Blockade Plus Vaccines Show Synergy in Early GBM Trials

BY BRIELLE BENYON

New Agents Show Promise in Treating Patients with IDH1-Mutant Low-Grade Glioma

New Agents Show Promise in Treating Patients with IDH1-Mutant Low-Grade Glioma

BY GINA COLUMBUS

FDA Approves Bevacizumab Biosimilar for 5 Cancer Types

FDA Approves Bevacizumab Biosimilar for 5 Cancer Types

BY BRIELLE BENYON

Quality of Life Is an Important Endpoint in Cancer Trials

Quality of Life Is an Important Endpoint in Cancer Trials

BY GIUSEPPE LOMBARDI, MD, PHD

App for Tracking GBM Symptoms May Fuel Cancer Advancements

App for Tracking GBM Symptoms May Fuel Cancer Advancements

BY BRIELLE BENYON

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.